<DOC>
	<DOCNO>NCT02149095</DOCNO>
	<brief_summary>TransCon PEG treprostinil novel prodrug form treprostinil , treprostinil reversibly conjugate via four-arm branch polyethylene glycol ( PEG ) molecule . Reversible couple treprostinil PEG allow modify extend pharmacokinetic profile achieve sustain plasma concentration treprostinil . This first investigation TransCon PEG treprostinil human . This study aim determine maximum tolerate dose ( MTD ) ass safety , tolerability pharmacokinetics escalate single dos subcutaneous injection TransCon PEG treprostinil .</brief_summary>
	<brief_title>Dose Escalation , MTD , Safety PK Study Single Dose SC Injection TransCon PEG Treprostinil Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1 . Subject give voluntary write informed consent participate study 2 . Subject healthy male age 18 50 year , inclusive , Screening 3 . Subjects must weigh 60 120 kg , inclusive , BMI 19.032.0 kg/m2 , inclusive Screening 4 . Subject medical history , physical examination , vital sign , ECG clinical laboratory result within normal limit consider clinically significant Investigator Screening 5 . Subject agree abstain take prescription medication 14 day prior checkin abstain take nonprescription medication ( except multivitamin ) herbal supplement 7 day prior checkin Baseline discharge study ( unless prescribe Investigator treat AE ) 6 . Subject agree abstain consume alcohol three day prior checkin discharge study 7 . Subject agree refrain strenuous exercise checkin discharge study 8 . Subject able communicate effectively study personnel consider reliable , willing cooperative term compliance protocol requirement 1 . Subject clinically relevant abnormality identify screen physical examination , 12lead ECG , laboratory examination 2 . Subject history anaphylaxis , previous document hypersensitivity reaction , clinically significant idiosyncratic reaction drug 3 . Subject clinically significant history neurological , cardiovascular , respiratory , endocrine , hematological , hepatic , renal , gastrointestinal , genitourinary , pulmonary , and/or musculoskeletal disease ; glaucoma ; psychiatric disorder , chronic disease , whether control medication 4 . Subject history postural hypotension , unexplained syncope 5 . Subject blood pressure le 85 mmHg systolic 50 mmHg diastolic Screening Baseline 6 . Subject pulse rate great 90 bpm sit rest 5 minute Screening Baseline 7 . Subject history hypertension 8 . Subject blood pressure great 150 mmHg systolic 90 mmHg diastolic Screening Baseline 9 . Subject predispose condition could interfere absorption , distribution , metabolism , excretion drug 10 . Subject test positive screen visit HIV infection , HBsAg , HCV antibody 11 . Subject currently use tobacco product history tobacco use within six month prior Baseline 12 . Subject history alcohol abuse history current impairment organ function reasonably related alcohol abuse 13 . Subject history current evidence abuse licit illicit drug positive urine screen drug abuse 14 . Subject history abnormal bleeding tendency 15 . Subject donate blood plasma lose significant volume blood ( great 450 mL ) within four week prior Baseline 16 . Subject participate investigational drug study within 30 day prior Screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>treprostinil</keyword>
</DOC>